Skip to main content

Advertisement

Log in

Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to assess the clinical activity and toxicity of 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma (DLBCL) who were treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone).

Methods

Patients who had been diagnosed with advanced stage (Ann Arbor III or IV) or bulky stage II DLBCL and achieved complete or partial response after six to eight cycles of R-CHOP were enrolled.

Results

A total of 16 patients were enrolled and treated with a single dose of 131I-rituximab as consolidation therapy after the completion of six or eight cycles of R-CHOP between December 2005 and June 2011. This trial was terminated before the scheduled enrollment owing to low recruitment. Among the 16 patients who were treated with consolidative 131I-rituximab, 6 achieved complete response (CR) after three cycles of R-CHOP, and another 9 patients further achieved CR after the completion of six or eight cycles of R-CHOP. During the median follow-up period of 73 months, only four patients (25 %) experienced relapse. Two-year relapse-free survival was 88 %, and 5-year relapse-free survival was 81 %. Grade 3 or 4 treatment-related toxicity occurred in four patients and included neutropenia and thrombocytopenia.

Conclusions

131I-rituximab showed promising efficacy as consolidation treatment for patients with DLBCL. A future randomized phase III study to confirm our results is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103(12):4429–4431. doi:10.1182/blood-2003-11-3883

    Article  CAS  PubMed  Google Scholar 

  2. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4):1259–1266

    CAS  PubMed  Google Scholar 

  3. Leahy MF, Turner JH (2011) Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117(1):45–52. doi:10.1182/blood-2010-02-269753

    Article  CAS  PubMed  Google Scholar 

  4. Kang HJ, Lee SS, Byun BH, Kim KM, Lim I, Choi CW, Suh C, Kim WS, Nam SH, Lee SI, Eom HS, Shin DY, Lim SM (2013) Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 71(4):945–953. doi:10.1007/s00280-013-2087-z

    Article  CAS  PubMed  Google Scholar 

  5. Kang HJ, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM (2011) Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). Asia Pac J Clin Oncol 7(2):136–145

    Article  PubMed  Google Scholar 

  6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795

    Article  CAS  PubMed  Google Scholar 

  7. Hermans J, Krol AD, van Groningen K, Kluin PM, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW (1995) International Prognostic Index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 86(4):1460–1463

    CAS  PubMed  Google Scholar 

  8. Lerner RE, Thomas W, Defor TE, Weisdorf DJ, Burns LJ (2007) The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin’s lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 13(4):486–492. doi:10.1016/j.bbmt.2006.12.452

    Article  PubMed  Google Scholar 

  9. Nabhan C, Mehta J (2012) Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy? Leuk Lymphoma 53(10):1859–1866. doi:10.3109/10428194.2012.679265

    Article  CAS  PubMed  Google Scholar 

  10. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244

    CAS  PubMed  Google Scholar 

  11. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in L (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578. doi:10.1200/JCO.2006.08.2305

    Article  PubMed  Google Scholar 

  12. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346

    Article  CAS  PubMed  Google Scholar 

  13. Wilder RB, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD (2002) International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer 94(12):3083–3088. doi:10.1002/cncr.10583

    Article  PubMed  Google Scholar 

  14. Damaj G, Ivanoff S, Coso D, Ysaebert L, Choquet S, Houillier C, Parcelier A, Abarah W, Marjanovic Z, Gressin R, Garidi R, Diouf M, Gac AC, Dupuis J, Troussard X, Morschhauseur F, Ghesquieres H, Soussain C, Lysa, Loc network F (2015) Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica 100(9):1199–1206. doi:10.3324/haematol.2015.126110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Armenian SH, Sun CL, Shannon T, Mills G, Francisco L, Venkataraman K, Wong FL, Forman SJ, Bhatia S (2011) Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 118(23):6023–6029. doi:10.1182/blood-2011-06-358226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pinana JL, Montesinos P, Martino R, Vazquez L, Rovira M, Lopez J, Batlle M, Figuera A, Barba P, Lahuerta JJ, Deben G, Perez-Lopez C, Garcia R, Rosique P, Lavilla E, Gascon A, Martinez-Cuadron D, Sanz MA (2014) Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol 93(2):299–307. doi:10.1007/s00277-013-1872-4

    Article  PubMed  Google Scholar 

  17. Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR (2012) Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 84(3):762–767. doi:10.1016/j.ijrobp.2011.12.067

    Article  PubMed  Google Scholar 

  18. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170–4176. doi:10.1200/JCO.2009.27.3441

    Article  PubMed  Google Scholar 

  19. Schaefer NG, Huang P, Buchanan JW, Wahl RL (2011) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. J Nucl Med 52(5):830–838. doi:10.2967/jnumed.110.085589

    Article  PubMed  PubMed Central  Google Scholar 

  20. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d’Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26(32):5156–5164. doi:10.1200/JCO.2008.17.2015

    Article  CAS  PubMed  Google Scholar 

  21. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O’Brien T, Gregory SA (2011) Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk 11(6):467–474. doi:10.1016/j.clml.2011.04.009

    Article  CAS  PubMed  Google Scholar 

  22. Jurczak W, Kisiel E, Sawczuk-Chabin J, Centkowski P, Knopinska-Posluszny W, Khan O (2015) The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. Contemp Oncol (Pozn) 19(1):43–47. doi:10.5114/wo.2015.50012

    CAS  Google Scholar 

  23. Yang DH, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh C, Lee JJ (2012) Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma 53(5):807–811. doi:10.3109/10428194.2011.635857

    Article  CAS  PubMed  Google Scholar 

  24. Mondello P, Pitini V, Arrigo C, Derenzini E, Mian M (2014) 90Y-Ibritumomab tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. Anticancer Res 34(9):5121–5125

    CAS  PubMed  Google Scholar 

  25. Fruchart C, Tilly H, Morschhauser F, Ghesquieres H, Bouteloup M, Ferme C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C (2014) Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Biol Blood Marrow Transplant 20(12):1905–1911. doi:10.1016/j.bbmt.2014.07.024

    Article  CAS  PubMed  Google Scholar 

  26. Han EJ, Lee SE, Kim SH, Sohn HS, Jung SE, Park G, Choi BO, Lee SN, Yang SW, Han K, Cho SG (2011) Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin(R)) for high-risk patients with diffuse large B-cell lymphoma. Ann Hematol 90(9):1075–1082. doi:10.1007/s00277-011-1191-6

    Article  CAS  PubMed  Google Scholar 

  27. Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166(3):382–389. doi:10.1111/bjh.12906

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M (2013) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31(13):1662–1668. doi:10.1200/JCO.2012.45.9453

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank the patients and their families who took part in this study, and the study coordinators Kyoung Ja Jung and Young Sub Lee who analyzed the dosimetry of this study. This study was supported by the Radiological Translational Research Program of the Korea Institute of Radiological and Medical Sciences (50450-2011/50441-2015) and the Nuclear R&D program of the Korea Science and the Engineering Foundation (NRF-2012M2A2A7013480) funded by the Ministry of Education, Science and Technology.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Hye Jin Kang or Sang Moo Lim.

Ethics declarations

Conflict of interest

The authors have declared no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shin, DY., Byun, B.H., Kim, K.M. et al. Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol 78, 825–831 (2016). https://doi.org/10.1007/s00280-016-3140-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3140-5

Keywords

Navigation